Literature DB >> 24309984

A new model for reimbursing genome-based cancer care.

Scott D Ramsey1, Sean D Sullivan.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 24309984      PMCID： PMC3903067          DOI： 10.1634/theoncologist.2013-0392

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  12 in total

1.  Drugs "refund" scheme proposed for England and Wales.

Authors:  Susan Mayor
Journal:  BMJ       Date:  2007-06-09

Review 2.  Translating next generation sequencing to practice: opportunities and necessary steps.

Authors:  Sitharthan Kamalakaran; Vinay Varadan; Angel Janevski; Nilanjana Banerjee; David Tuck; W Richard McCombie; Nevenka Dimitrova; Lyndsay N Harris
Journal:  Mol Oncol       Date:  2013-05-15       Impact factor: 6.603

3.  'Master protocol' aims to revamp cancer trials.

Authors:  Heidi Ledford
Journal:  Nature       Date:  2013-06-13       Impact factor: 49.962

4.  Can't get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products.

Authors:  Adrian Towse; Louis P Garrison
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

5.  Access with evidence development schemes: a framework for description and evaluation.

Authors:  Christopher J McCabe; Tania Stafinski; Richard Edlin; Devidas Menon
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 6.  Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers.

Authors:  Josh J Carlson; Sean D Sullivan; Louis P Garrison; Peter J Neumann; David L Veenstra
Journal:  Health Policy       Date:  2010-03-11       Impact factor: 2.980

7.  The Cancer Genome Atlas Pan-Cancer analysis project.

Authors:  John N Weinstein; Eric A Collisson; Gordon B Mills; Kenna R Mills Shaw; Brad A Ozenberger; Kyle Ellrott; Ilya Shmulevich; Chris Sander; Joshua M Stuart
Journal:  Nat Genet       Date:  2013-10       Impact factor: 38.330

Review 8.  Which drug, and when, for patients with BRAF-mutant melanoma?

Authors:  Sekwon Jang; Michael B Atkins
Journal:  Lancet Oncol       Date:  2013-02       Impact factor: 41.316

Review 9.  Progress in molecular-based management of differentiated thyroid cancer.

Authors:  Mingzhao Xing; Bryan R Haugen; Martin Schlumberger
Journal:  Lancet       Date:  2013-03-22       Impact factor: 79.321

Review 10.  Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers?

Authors:  Tomoya Yokota
Journal:  Anticancer Agents Med Chem       Date:  2012-02       Impact factor: 2.505
View more
  7 in total

Review 1.  Precision Medicine: From Science To Value.

Authors:  Geoffrey S Ginsburg; Kathryn A Phillips
Journal:  Health Aff (Millwood)       Date:  2018-05       Impact factor: 6.301

Review 2.  Stated and Revealed Preferences for Funding New High-Cost Cancer Drugs: A Critical Review of the Evidence from Patients, the Public and Payers.

Authors:  Tatjana E MacLeod; Anthony H Harris; Ajay Mahal
Journal:  Patient       Date:  2016-06       Impact factor: 3.883

3.  New Medicare Coverage Policy for Next-Generation Tumor Sequencing: A Key Shift in Coverage Criteria With Broad Implications Beyond Medicare.

Authors:  K A Phillips; J R Trosman; C B Weldon; M P Douglas
Journal:  JCO Precis Oncol       Date:  2018-11-08

Review 4.  Genetics, biomarkers, hereditary cancer syndrome diagnosis, heterogeneity and treatment: a review.

Authors:  Henry T Lynch; Kristen Drescher; Joseph Knezetic; Stephen Lanspa
Journal:  Curr Treat Options Oncol       Date:  2014-09

5.  Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options.

Authors:  Rositsa Koleva-Kolarova; James Buchanan; Heleen Vellekoop; Simone Huygens; Matthijs Versteegh; Maureen Rutten-van Mölken; László Szilberhorn; Tamás Zelei; Balázs Nagy; Sarah Wordsworth; Apostolos Tsiachristas
Journal:  Appl Health Econ Health Policy       Date:  2022-04-04       Impact factor: 3.686

6.  Innovations that reach the patient: early health technology assessment and improving the chances of coverage and implementation.

Authors:  W H van Harten; V P Retèl
Journal:  Ecancermedicalscience       Date:  2016-10-28

7.  Towards Routine Implementation of Liquid Biopsies in Cancer Management: It Is Always Too Early, until Suddenly It Is Too Late.

Authors:  Maarten J IJzerman; Jasper de Boer; Arun Azad; Koen Degeling; Joel Geoghegan; Chelsee Hewitt; Frédéric Hollande; Belinda Lee; Yat Ho To; Richard W Tothill; Gavin Wright; Jeanne Tie; Sarah-Jane Dawson
Journal:  Diagnostics (Basel)       Date:  2021-01-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.